

Geraldine Ferron-brady

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/336783/publications.pdf>

Version: 2024-02-01

6
papers

210
citations

1684188

5
h-index

1872680

6
g-index

6
all docs

6
docs citations

6
times ranked

432
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum, 2020, 4, pkz093.	2.9	126
2	Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all- <i>trans</i> retinoic acid in acute myeloid leukemia across subtypes. Haematologica, 2019, 104, 1156-1167.	3.5	50
3	DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PvD) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2020, 136, 4-4.	1.4	18
4	An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers. Journal of Clinical Pharmacology, 2021, 61, 125-137.	2.0	7
5	Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 709-722.	2.5	7
6	Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	2.5	2